Cryoport, Inc. (CYRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 79 | 223 | 223 | 237 | 233 | 176 | 186 | 195 |
| Operating profit | $m | -37 | -40 | ||||||
| Net profit | $m | -33 | -276 | -276 | -37 | -100 | 78 | -36 | -39 |
| EPS reported | $ | 1.40 | -0.82 | ||||||
| Operating cashflow per share | $ | -0.17 | 0.16 | ||||||
| Capex per share | $ | 0.39 | 0.56 | ||||||
| FCF per share | $ | -0.56 | -0.40 | ||||||
| Free cash flow | $m | -28 | -20 | ||||||
| Net debt | $m | -225 | -210 | ||||||
| Book value equity | $m | 503 | 491 | ||||||
| Book value per share | $ | 10.04 | 9.73 | ||||||
| Number of shares | m | 50.07 | 50.44 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 6.86 | - | ||||||
| P/B LTM | x | 0.96 | 0.98 | ||||||
| P/S LTM | x | 2.73 | 2.58 | ||||||
| P/FCF LTM | x | -17.12 | -23.64 | ||||||
| EV/EBITDA LTM | x | -219.80 | -147.30 | ||||||
| EV/Sales LTM | x | 2.62 | 4.07 | ||||||
| Earnings Yield LTM | % | +14.58% | -4.55% | ||||||
| FCF Yield | % | -5.84% | -4.23% | ||||||
| Quality | |||||||||
| ROE | % | +15.58% | -7.25% | ||||||
| ROIC | % | -5.00% | -5.46% | ||||||
| Operating margin | % | -20.89% | -21.25% | ||||||
| Gross margin | % | +47.14% | +47.08% | ||||||
| FCF/Sales | % | -15.94% | -10.91% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -24.47% | -20.07% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.12 | -0.09 | ||||||
| Net Debt/EBITDA | x | 9.43 | 11.90 | ||||||
| EBIT/Net interest | x | -15.59 | -18.78 | ||||||
| Net debt/market cap | % | +38.77% | +23.45% | ||||||
| Net debt/Equity | x | -0.45 | -0.43 | ||||||
| Gross debt/equity | x | 0.46 | 0.47 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free